Morgan Stanley analyst Matthew Harrison upgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Underweight to Equal-Weight and raises the price target from $4 to $8.
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.